There are questions on whether epacadostat doses used in the ECHO-301 trial could effectively inhibit IDO1 activity in the tumor microenvironment and whether targeting multiple enzymes in the KYN pathway to control Try metabolism would benefit to these patients (58). This evidence concerns the gene IDO1 and neoplasm.